Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.

Butler AM, Cetin K, Hernandez RK, Diane Reams B, Overman RA, I Kim J, Hirsch BR, Abernethy AP, Liede A, Alan Brookhart M.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):229-238. doi: 10.1002/pds.4360. Epub 2018 Jan 7.

PMID:
29316026
2.

Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.

Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, Abernethy AP, Simantov R, Borham A, George DJ.

Cancer Invest. 2017 May 28;35(5):333-344. doi: 10.1080/07357907.2017.1289215. Epub 2017 Apr 3.

PMID:
28368708
3.

Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity.

Hirsch BR, Locke SC, Abernethy AP.

J Oncol Pract. 2016 Apr;12(4):e350-8. doi: 10.1200/JOP.2015.005090. Epub 2016 Mar 29.

4.

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH.

JAMA Oncol. 2016 Jun 1;2(6):772-9. doi: 10.1001/jamaoncol.2015.6315.

5.

Sequential Therapy in Metastatic Renal Cell Carcinoma.

Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, Fleming MT, Vogelzang NJ.

J Kidney Cancer VHL. 2016 Apr 5;3(1):23-35. doi: 10.15586/jkcvhl.2016.46. eCollection 2016. Review.

6.

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR.

J Oncol Pract. 2015 Nov;11(6):491-7. doi: 10.1200/JOP.2015.004929. Epub 2015 Sep 1.

PMID:
26330533
7.

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.

Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH.

JAMA Oncol. 2015 May;1(2):158-66. doi: 10.1001/jamaoncol.2015.43.

PMID:
26181015
8.

Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention.

Hess CN, Roe MT, Clare RM, Chiswell K, Kelly J, Tcheng JE, Hagstrom E, James SK, Khouri MG, Hirsch BR, Kong DF, Abernethy AP, Krucoff MW.

J Am Heart Assoc. 2015 Jul 6;4(7). pii: e001779. doi: 10.1161/JAHA.115.001779.

9.

Deferred systemic therapy in patients with metastatic renal cell carcinoma.

Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ.

Clin Genitourin Cancer. 2015 Jun;13(3):e159-66. doi: 10.1016/j.clgc.2014.12.017. Epub 2014 Dec 31.

PMID:
25770767
10.

Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.

Dinan MA, Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2015 Jan;13(1):e1-7. Review.

PMID:
25583775
11.

The impact of specialty pharmaceuticals as drivers of health care costs.

Hirsch BR, Balu S, Schulman KA.

Health Aff (Millwood). 2014 Oct;33(10):1714-20. doi: 10.1377/hlthaff.2014.0558.

PMID:
25288414
12.

Biosimilars: a cure to the U.S. health care cost conundrum?

Hirsch BR, Lyman GH.

Blood Rev. 2014 Nov;28(6):263-8. doi: 10.1016/j.blre.2014.08.003. Epub 2014 Sep 16. Review.

PMID:
25260225
13.

Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.

Hirsch BR, Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.

Med Oncol. 2014 Sep;31(9):156. doi: 10.1007/s12032-014-0156-8. Epub 2014 Aug 14.

PMID:
25115744
14.

Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?

Hirsch BR, George DJ, Harrison MR.

Clin Adv Hematol Oncol. 2014 Mar;12(3):163-71. Review.

PMID:
24927264
15.

Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.

Mitchell AP, Hirsch BR, Abernethy AP.

Trials. 2014 Mar 25;15:92. doi: 10.1186/1745-6215-15-92.

16.

A comparison of FDA and EMA drug approval: implications for drug development and cost of care.

Howie LJ, Hirsch BR, Abernethy AP.

Oncology (Williston Park). 2013 Dec;27(12):1195, 1198-1200, 1202 passim. No abstract available.

17.

Comparative effectiveness research: moving medical oncology forward.

Hirsch BR, Zafar SY.

Semin Radiat Oncol. 2014 Jan;24(1):49-53. doi: 10.1016/j.semradonc.2013.08.005. Review.

PMID:
24314342
18.

Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.

Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.

J Oncol Pract. 2014 Mar;10(2):e63-72. doi: 10.1200/JOP.2013.001180. Epub 2013 Nov 26.

PMID:
24281152
19.

Will biosimilars gain momentum?

Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1291-7. Review.

PMID:
24142828
20.

The ethics of health information technology in oncology: emerging isssues from both local and global perspectives.

LeBlanc TW, Shulman LN, Yu PP, Hirsch BR, Abernethy AP.

Am Soc Clin Oncol Educ Book. 2013:136-42. doi: 10.1200/EdBook_AM.2013.33.136. Review.

Supplemental Content

Loading ...
Support Center